Tech Session I: Nanomedicine and Nanoscale Delivery (Focus: Gene)
Overcoming Chemoresistance in Colorectal Cancer by FcRn-Driven Nucleic Acid Delivery
Tuesday, July 15, 2025
10:54 AM - 11:05 AM EDT
Location: 121 B/C
Introduction: Colorectal cancer (CRC) remains a significant global health challenge, with chemotherapy often compromised by drug resistance linked to dysregulated microRNA (miRNA) profiles (1). Restoring physiological miRNA levels offers a promising strategy to reverse resistance. Despite this potential, oral miRNA delivery is limited by gastrointestinal degradation and poor targeting (2). To address these limitations, we are developing a dual-nanotherapy that exploits the neonatal Fc receptor (FcRn), overexpressed in CRC tissues (3), to enhance delivery specificity and chemosensitivity.
Learning Objectives:
At the completion of this activity, participants will know
Define the challenges of oral miRNA delivery and strategies to enhance stability and specificity.
Describe how targeting FcRn improves the efficacy of orally administered therapeutics.
Describe how integrating targeted gene therapy with chemotherapy helps reverse chemoresistance.
Georgios Sotiriou – Principal Researcher, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet; Bruno Sarmento – Principal Researcher, Instituto de Investigação e Inovação em Saúde (i3S)
